Lundbeck A/S

Company

Also known as: H. Lundbeck A/S

Related News

Global Schizophrenia Drugs Market Projected to Reach USD 15.8 Billion by 2036

May 09, 2026

The global schizophrenia drugs market is projected to grow from USD 9.1 billion in 2026 to USD 15.8 billion by 2036 at a 5.8% CAGR. Long-acting injectables and second-generation antipsychotics lead the market.

Lundbeck's Bocunebart Meets Primary Endpoint in Phase IIb Migraine Prevention Trial

Feb 13, 2026

Lundbeck's investigational anti-PACAP antibody bocunebart demonstrated statistically significant reduction in monthly migraine days versus placebo in a phase IIb trial of patients who had failed prior preventive treatments, positioning the company for phase III discussions with regulators.